For the past two years, standalone Medicare drug plan premiums have been held down by something most enrollees have never heard of and none of them signed up for. It was temporary by design, and Medicare has now confirmed the end date. What that means for any particular household will not be knowable until September.
What the demonstration was doing
The Part D Premium Stabilization Demonstration began in calendar year 2025 as a voluntary program for standalone prescription drug plans. Its purpose, in CMS’s framing, was to address volatility and variation in standalone premiums after the benefit redesign required by the Inflation Reduction Act.
That redesign was good news for people with high drug costs — it capped out-of-pocket spending and restructured who pays what. But redesigns shift risk, and insurers pricing an unfamiliar benefit tend to price defensively. The demonstration cushioned the result so that premiums for standalone drug plans did not spike or scatter wildly while sponsors learned what the new benefit actually cost them.
In its July 28, 2026 release, CMS announced the conclusion of that demonstration, stating it “will discontinue the demonstration at the end of CY 2026 to return the program to operating under traditional market conditions in CY 2027.” The agency’s stated reason is that bid analysis indicates plan sponsors now have sufficient experience under the redesigned benefit to support their pricing assumptions.
Free retirement updates: Social Security, Medicare, and retirement rules are easier to use when the fine print is translated. The free Retirement Shield newsletter does that a couple of times a week. Subscribe free.
The $296.05 figure and what it is not
The same July 28 announcement sets the national average monthly bid amount for 2027 at $296.05. This number gets misreported constantly, so it is worth being precise about what it represents.
It is a technical benchmark: the enrollment-weighted average of what plans bid to provide the standard drug benefit. It feeds the formulas that determine federal subsidy levels and the base beneficiary premium. It is not what anyone pays. No enrollee will see $296.05 on a statement, and a household that reads it as a forecast of their own premium will badly misjudge their budget.
The related figure that does appear downstream is the 2027 base beneficiary premium of $41.33 — again a formula input rather than a price tag, since actual plan premiums vary widely above and below it by plan and region.
Why nobody can tell you your 2027 premium yet
This is the part that matters operationally. Plan-specific 2027 premiums are not published and are not knowable today. They arrive with the annual Medicare plan landscape release, which CMS indicates comes in mid-to-late September 2026.
Any source claiming to know what a specific drug plan will cost next year before that release is guessing. That includes agents, mailers, and websites — and the gap between now and September is exactly the window in which marketing arrives promising certainty that does not exist.
It is also worth noting the guardrail that remains in place. The Inflation Reduction Act caps annual growth in the base beneficiary premium at 6 percent through 2029. That cap constrains one input; it does not constrain what any individual plan charges.
The shopping instruction this actually generates
The useful takeaway is not a number. It is a calendar item and a warning against autopilot.
Medicare’s Open Enrollment runs October 15 through December 7. With the landscape data landing in mid-to-late September, that leaves roughly three to four weeks to compare before the window opens, and about eight weeks total to act. For a stabilized year, letting a plan auto-renew was a defensible choice. For a year in which a premium-smoothing program is being withdrawn and plans are pricing under traditional market conditions, auto-renewal is a decision to accept whatever the plan does.
Three things make that comparison faster when the time comes. Have a current list of every prescription with its exact dosage, since drug-by-drug formulary differences drive the total cost far more than the premium does. Watch for the Annual Notice of Change, which plans must send in the fall and which states in writing what is changing about premium, deductible and formulary for the coming year — the single most useful document most enrollees throw away. And compare total annual cost rather than monthly premium; a lower premium with a worse formulary routinely costs more over twelve months.
Households with limited income should also check eligibility for Extra Help, the low-income subsidy that reduces Part D premiums and cost sharing, which is unaffected by this demonstration ending.
What is settled and what is not
Settled: the demonstration ends after calendar year 2026, and CMS has said so in its own release. The 2027 national average monthly bid amount is $296.05.
Not settled: what any individual pays. That is the number households care about, it is the number nobody has, and it shows up in September. Marking that date is the only action available in August.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
